Daiichi Life Insurance Co. Ltd. Raises Stock Holdings in Amgen Inc. $AMGN

Daiichi Life Insurance Co. Ltd. lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 3.9% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,660 shares of the medical research company’s stock after buying an additional 1,312 shares during the quarter. Daiichi Life Insurance Co. Ltd.’s holdings in Amgen were worth $12,551,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. grew its stake in shares of Amgen by 1.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 58,532 shares of the medical research company’s stock valued at $21,196,000 after acquiring an additional 596 shares during the period. CFO4Life Group LLC increased its holdings in Amgen by 2.6% in the 2nd quarter. CFO4Life Group LLC now owns 1,340 shares of the medical research company’s stock worth $485,000 after acquiring an additional 34 shares in the last quarter. Madison Wealth Partners Inc increased its holdings in Amgen by 42.1% in the 2nd quarter. Madison Wealth Partners Inc now owns 996 shares of the medical research company’s stock worth $361,000 after acquiring an additional 295 shares in the last quarter. X Square Capital LLC lifted its holdings in Amgen by 3.8% during the second quarter. X Square Capital LLC now owns 10,908 shares of the medical research company’s stock valued at $3,950,000 after purchasing an additional 397 shares in the last quarter. Finally, Emerald Investment Advisers LLC lifted its holdings in Amgen by 32.4% during the second quarter. Emerald Investment Advisers LLC now owns 15,256 shares of the medical research company’s stock valued at $5,525,000 after purchasing an additional 3,735 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Solid operating performance and dividend support the valuation. Amgen’s second-quarter results exceeded expectations, with revenue rising year over year and earnings per share topping consensus. Continued growth and the company’s dividend are helping support investor confidence. Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation
• Positive Sentiment: Analysts raised their outlook. Argus increased its price target to $460 from $375 while maintaining a Buy rating, citing the latest quarterly performance and progress across Amgen’s drug portfolio. Separate reports also highlighted favorable forecasts from Mizuho and Cantor Fitzgerald, reinforcing the bullish analyst sentiment. Amgen gets a fresh target
• Positive Sentiment: Tarlatamab development advanced. Amgen’s Phase 3 DeLLphi-315 study is evaluating a subcutaneous injection of tarlatamab against the current intravenous infusion approach in lung cancer. A successful shot formulation could improve convenience and broaden the commercial potential of the drug. Amgen advances tarlatamab shot versus infusion in Phase 3 lung cancer study
• Positive Sentiment: Trading momentum and options activity were unusually strong. Amgen was identified as a momentum stock after a substantial recent share-price rally, while call-option volume surged well above typical levels, suggesting increased bullish positioning.
• Neutral Sentiment: Valuation is becoming a consideration. With the stock near its recent high and analysts raising targets, some commentary questioned whether much of the favorable news is already reflected in the share price, which could limit near-term upside.

Insider Activity

In related news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,222 shares of company stock worth $2,540,926 over the last ninety days. Insiders own 0.85% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $439.33 on Friday. The firm has a market cap of $237.52 billion, a price-to-earnings ratio of 27.30, a P/E/G ratio of 3.17 and a beta of 0.41. The firm has a fifty day moving average price of $379.03 and a 200 day moving average price of $361.95. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $443.20. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 22.92 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is 62.65%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Bank of America increased their price objective on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Citigroup lifted their target price on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Daiwa Securities Group dropped their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a report on Wednesday, May 13th. Oppenheimer raised their price target on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Finally, Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus target price of $380.43.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.